See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Natural Disasters
Social Media
Artificial Intelligence
Tariffs
Donald Trump
Stock Markets
UK Economy
European Union
Vladimir Putin
Inflation
Soccer
Published • loading... • Updated

Pirtobrutinib’s Star Turn in Relapsed/Refractory CLL May Get an Encore

Summary by Medscape
New data could turn third-line treatment into an earlier therapy.

2 Articles

All
Left
Center
Right
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News

Pirtobrutinib’s Star Turn May Get an Encore

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have developed resistance to other treatments. “Pirtobrutinib has added an entire line of therapy for patients with progression on covalent BTK [Bruton’s tyrosine kinase] inhibitors and […] The post Pirtobrutinib’s Star Turn May Get an Encore first appeared o…

Read Full Article
MedscapeMedscape

Pirtobrutinib’s Star Turn in Relapsed/Refractory CLL May Get an Encore

New data could turn third-line treatment into an earlier therapy.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Friday, March 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA

FDA

Medical

Medical

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal